Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Primary care of transgender individuals

Jamie Feldman, MD, PhD
Madeline B Deutsch, MD, MPH
Section Editor
Joann G Elmore, MD, MPH
Deputy Editor
Lee Park, MD, MPH


In addition to gender-affirming medical care, transgender people have primary and preventive health care needs that are similar to the general population. Depending on an individual's history of gender-affirming care, primary and preventive care may require special considerations. Transgender patients often experience discrimination in the health care setting and lack of access to medical personnel competent in transgender medicine [1,2]. This results in lack of access to preventive health services and timely treatment of routine health problems [3-6].

This topic will provide an overview for providing primary care to transgender patients. The epidemiology, pathophysiology, and diagnosis as well as the hormonal and surgical treatment of transgender patients are discussed elsewhere. (See "Transgender women: Evaluation and management".)


The term "transgender" is generally used to describe a diverse group of individuals whose gender identity or expression differs from that assigned at birth (table 1). Primary care providers should be familiar with commonly used terms (table 1) and the diversity of identities within the transgender community. Natal sex refers to the sex the patient was assigned at birth. Transgender women (male to female, MTF) have a female gender identity and were assigned a male sex at birth and transgender men (female to male, FTM) have a male gender identity and were assigned a female sex at birth. Gender-affirming care includes hormone therapy and gender-related surgeries, as well as other procedures such as hair removal or speech therapy.


The role of the primary care provider for transgender patients includes the tasks typical for all patients (eg, primary and secondary prevention), in addition to the specific needs of transgendered individuals. For example, primary care clinicians may be involved in providing medical documentation of a patient's gender, navigating insurance coverage for gender-related interventions, and providing letters for change of gender on identification (eg, passport, driver's license). Referrals may also be sought for sex reassignment surgeries, voice therapy, hair removal through laser or electrolysis, or hair transplant [7].

Not every primary care clinician will be able to offer all elements of comprehensive transgender care; however, every clinician can become comfortable in working with transgender patients to meet their health care needs. It is important that primary care providers be aware that patients may vary widely in terms of anatomy and hormonal status when they present, and these attributes may further change over time.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jul 20, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Daniel H, Butkus R, Health and Public Policy Committee of American College of Physicians. Lesbian, Gay, Bisexual, and Transgender Health Disparities: Executive Summary of a Policy Position Paper From the American College of Physicians. Ann Intern Med 2015; 163:135.
  2. Schuster MA, Reisner SL, Onorato SE. Beyond Bathrooms--Meeting the Health Needs of Transgender People. N Engl J Med 2016; 375:101.
  3. Grant JM, Mottet LA, Tanis J, et al. Injustice at every turn: A report of the National Transgender Discrimination Survey. National Center for Transgender Equality and National Gay and Lesbian Task Force; Washington, DC 2011.
  4. Institute of Medicine. The health of lesbian, gay, bisexual, and transgender people: building a foundation for better understanding. Washington DC: National Academies Press; 2011 www.iom.edu (Accessed on November 19, 2014).
  5. Kammerer N, Mason T, Connors M. Transgender health and social service needs in the context of HIV risk. Int J Transgend 1999; 3:1.
  6. Vogel L. Screening programs overlook transgender people. CMAJ 2014; 186:823.
  7. Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgend 2012; 13:165.
  8. Sperber J, Landers S, Lawrence S. Access to health care for transgendered persons: Results of a needs assessment in Boston. Int J Transgend 2005; 8:75.
  9. Center of Excellence for Transgender Health. Primary care protocol for transgender patient care. University of California; San Francisco, CA 2011.
  10. Baba T, Endo T, Honnma H, et al. Association between polycystic ovary syndrome and female-to-male transsexuality. Hum Reprod 2007; 22:1011.
  11. Mueller A, Gooren LJ, Naton-Schötz S, et al. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. J Clin Endocrinol Metab 2008; 93:1408.
  12. Bosinski HA, Peter M, Bonatz G, et al. A higher rate of hyperandrogenic disorders in female-to-male transsexuals. Psychoneuroendocrinology 1997; 22:361.
  13. Bauer GR, Travers R, Scanlon K, Coleman TA. High heterogeneity of HIV-related sexual risk among transgender people in Ontario, Canada: a province-wide respondent-driven sampling survey. BMC Public Health 2012; 12:292.
  14. Bockting WO, Robinson BE, Rosser BR. Transgender HIV prevention: a qualitative needs assessment. AIDS Care 1998; 10:505.
  15. Crosby RA, Pitts NL. Caught between different worlds: how transgendered women may be "forced" into risky sex. J Sex Res 2007; 44:43.
  16. Melendez RM, Pinto R. 'It's really a hard life': love, gender and HIV risk among male-to-female transgender persons. Cult Health Sex 2007; 9:233.
  17. Nemoto T, Operario D, Keatley J, et al. HIV risk behaviors among male-to-female transgender persons of color in San Francisco. Am J Public Health 2004; 94:1193.
  18. Sausa LA, Keatley J, Operario D. Perceived risks and benefits of sex work among transgender women of color in San Francisco. Arch Sex Behav 2007; 36:768.
  19. Feldman J, Romine RS, Bockting WO. HIV risk behaviors in the U.S. transgender population: prevalence and predictors in a large internet sample. J Homosex 2014; 61:1558.
  20. Nuttbrock L, Rosenblum A, Blumenstein R. Transgender identity affirmation and mental health. Int J Transgend 2002; 6:1.
  21. Lombardi EL, Wilchins RA, Priesing D, Malouf D. Gender violence: transgender experiences with violence and discrimination. J Homosex 2001; 42:89.
  22. Schlatterer K, Yassouridis A, von Werder K, et al. A follow-up study for estimating the effectiveness of a cross-gender hormone substitution therapy on transsexual patients. Arch Sex Behav 1998; 27:475.
  23. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132.
  24. Asscheman H, Giltay EJ, Megens JA, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011; 164:635.
  25. Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008; 93:19.
  26. Feldman J. Initiating feminizing hormone therapy over age 50: results and challenges. Paper presented at World Professional Association for Transgender Health Biennial Symposium, Atlanta, GA, September 27, 2011.
  27. Wierckx K, Elaut E, Declercq E, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol 2013; 169:471.
  28. Wierckx K, Mueller S, Weyers S, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med 2012; 9:2641.
  29. Feldman J, Safer J. Hormone therapy in adults: suggested revisions to the sixth version of the standards of care. Int J Transgend 2009; 11:146.
  30. Gooren LJ, Wierckx K, Giltay EJ. Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern. Eur J Endocrinol 2014; 170:809.
  31. Elbers JM, Giltay EJ, Teerlink T, et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf) 2003; 58:562.
  32. Elbers JM, Asscheman H, Seidell JC, Gooren LJ. Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am J Physiol 1999; 276:E317.
  33. Koh-Banerjee P, Wang Y, Hu FB, et al. Changes in body weight and body fat distribution as risk factors for clinical diabetes in US men. Am J Epidemiol 2004; 159:1150.
  34. Resnick HE, Valsania P, Halter JB, Lin X. Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. J Epidemiol Community Health 2000; 54:596.
  35. Glueck CJ, Lang J, Hamer T, Tracy T. Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women. J Lab Clin Med 1994; 123:59.
  36. Goldenberg NM, Wang P, Glueck CJ. An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia. Clin Chim Acta 2003; 332:11.
  37. Ott J, Aust S, Promberger R, et al. Cross-sex hormone therapy alters the serum lipid profile: a retrospective cohort study in 169 transsexuals. J Sex Med 2011; 8:2361.
  38. Feldman J. Medical and surgical management of the transgender patient: What the primary care clinician needs to know. Fenway guide to lesbian, gay, bisexual, and transgender health 2008; :372.
  39. Jones RA, Schultz CG, Chatterton BE. A longitudinal study of bone density in reassigned transsexuals. Bone 2009; 44:S126.
  40. Campion JM, Maricic MJ. Osteoporosis in men. Am Fam Physician 2003; 67:1521.
  41. Mueller A, Kiesewetter F, Binder H, et al. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Metab 2007; 92:3470.
  42. Haraldsen IR, Haug E, Falch J, et al. Cross-sex pattern of bone mineral density in early onset gender identity disorder. Horm Behav 2007; 52:334.
  43. Van Caenegem E, Wierckx K, Taes Y, et al. Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. J Clin Endocrinol Metab 2012; 97:2503.
  44. Turner A, Chen TC, Barber TW, et al. Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects. Clin Endocrinol (Oxf) 2004; 61:560.
  45. van Kesteren P, Lips P, Gooren LJ, et al. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin Endocrinol (Oxf) 1998; 48:347.
  46. Goh HH, Ratnam SS. Effects of hormone deficiency, androgen therapy and calcium supplementation on bone mineral density in female transsexuals. Maturitas 1997; 26:45.
  47. Ganly I, Taylor EW. Breast cancer in a trans-sexual man receiving hormone replacement therapy. Br J Surg 1995; 82:341.
  48. Pritchard TJ, Pankowsky DA, Crowe JP, Abdul-Karim FW. Breast cancer in a male-to-female transsexual. A case report. JAMA 1988; 259:2278.
  49. Symmers WS. Carcinoma of breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics. Br Med J 1968; 2:83.
  50. Brown GR, Jones KT. Incidence of breast cancer in a cohort of 5,135 transgender veterans. Breast Cancer Res Treat 2015; 149:191.
  51. Gooren L, Bowers M, Lips P, Konings IR. Five new cases of breast cancer in transsexual persons. Andrologia 2015; 47:1202.
  52. Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2008; 159:197.
  53. Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med 2013; 10:3129.
  54. Lawrence AA. Vaginal neoplasia in a male-to-female transsexual: Case report, review of the literature, and recommendations for cytological screening. Int J Transgend 2001; 5.
  55. van Trotsenburg MA. Gynecological aspects of transgender healthcare. Int J Transgend 2009; 11:238.
  56. Moyer VA, U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 156:880.
  57. Gooren L, Morgentaler A. Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia 2014; 46:1156.
  58. Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996; 276:1904.
  59. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 2006; 68:1263.
  60. Eyler AE, Whittle S. FTM breast cancer: Community awareness and illustrative cases. Paper presented at 17th Biennial Symposium of the Harry Benjamin International Gender Dysphoria Association, Galveston, TX, November 2001. www.symposion.com/ijt/hbigda/2001/41_eyler.htm (Accessed on January 01, 2012).
  61. Peitzmeier SM, Reisner SL, Harigopal P, Potter J. Female-to-male patients have high prevalence of unsatisfactory Paps compared to non-transgender females: implications for cervical cancer screening. J Gen Intern Med 2014; 29:778.
  62. Miller N, Bédard YC, Cooter NB, Shaul DL. Histological changes in the genital tract in transsexual women following androgen therapy. Histopathology 1986; 10:661.
  63. Marrazzo JM, Koutsky LA, Kiviat NB, et al. Papanicolaou test screening and prevalence of genital human papillomavirus among women who have sex with women. Am J Public Health 2001; 91:947.
  64. Valanis BG, Bowen DJ, Bassford T, et al. Sexual orientation and health: comparisons in the women's health initiative sample. Arch Fam Med 2000; 9:843.
  65. Grynberg M, Fanchin R, Dubost G, et al. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online 2010; 20:553.
  66. Centers for Disease Control and Prevention. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae--2014. MMWR Recomm Rep 2014; 63:1.
  67. Corneil TA, Eisfeld JH, Botzer M. Proposed changes to diagnoses related to gender identity in the DSM: A World Professional Association for Transgender Health consensus paper regarding the potential impact on access to health care for transgender persons. Int J Transgend 2010; 12:107.